Malaysia Biotech Head Calls For More Private Involvement
This article was originally published in PharmAsia News
The head of Malaysia's biotechnology agency, BiotechCorp, called for more involvement by the private sector if the nation is to meet its goal of doubling the number of biotech firms by the end of this year. Of 63 Malaysian biotechs, 25 are in the health care business. BiotechCorp CEO Datuk Iskandar Mizal Mahmood said government funding needs to be complemented by private financing and capital markets if the goal of 120 biotech firms in Malaysia by the end of the year is to be met. After that, the government's master plan aims for a commercialization phase between 2011 and 2015. (Click here for more
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?